Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development

The emergence of the COVID-19 outbreak at the end of 2019, caused by the novel coronavirus SARS-CoV-2, has, to date, led to over 13.6 million infections and nearly 600,000 deaths. Consequently, there is an urgent need to better understand the molecular factors triggering immune defense against the v...

Full description

Bibliographic Details
Main Authors: Vipin Ranga, Erik Niemelä, Mahlet Z. Tamirat, John E. Eriksson, Tomi T. Airenne, Mark S. Johnson
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/8/3/408
_version_ 1797561591286202368
author Vipin Ranga
Erik Niemelä
Mahlet Z. Tamirat
John E. Eriksson
Tomi T. Airenne
Mark S. Johnson
author_facet Vipin Ranga
Erik Niemelä
Mahlet Z. Tamirat
John E. Eriksson
Tomi T. Airenne
Mark S. Johnson
author_sort Vipin Ranga
collection DOAJ
description The emergence of the COVID-19 outbreak at the end of 2019, caused by the novel coronavirus SARS-CoV-2, has, to date, led to over 13.6 million infections and nearly 600,000 deaths. Consequently, there is an urgent need to better understand the molecular factors triggering immune defense against the virus and to develop countermeasures to hinder its spread. Using in silico analyses, we showed that human major histocompatibility complex (MHC) class I cell-surface molecules vary in their capacity for binding different SARS-CoV-2-derived epitopes, i.e., short sequences of 8-11 amino acids, and pinpointed five specific SARS-CoV-2 epitopes that are likely to be presented to cytotoxic T-cells and hence activate immune responses. The identified epitopes, each one of nine amino acids, have high sequence similarity to the equivalent epitopes of SARS-CoV virus, which are known to elicit an effective T cell response in vitro. Moreover, we give a structural explanation for the binding of SARS-CoV-2-epitopes to MHC molecules. Our data can help us to better understand the differences in outcomes of COVID-19 patients and may aid the development of vaccines against SARS-CoV-2 and possible future outbreaks of novel coronaviruses.
first_indexed 2024-03-10T18:17:07Z
format Article
id doaj.art-9737d2b7623a4ad4955a11704360de5e
institution Directory Open Access Journal
issn 2076-393X
language English
last_indexed 2024-03-10T18:17:07Z
publishDate 2020-07-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj.art-9737d2b7623a4ad4955a11704360de5e2023-11-20T07:39:46ZengMDPI AGVaccines2076-393X2020-07-018340810.3390/vaccines8030408Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine DevelopmentVipin Ranga0Erik Niemelä1Mahlet Z. Tamirat2John E. Eriksson3Tomi T. Airenne4Mark S. Johnson5Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandCell Biology, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandStructural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandCell Biology, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandStructural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandStructural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, 20520 Turku, FinlandThe emergence of the COVID-19 outbreak at the end of 2019, caused by the novel coronavirus SARS-CoV-2, has, to date, led to over 13.6 million infections and nearly 600,000 deaths. Consequently, there is an urgent need to better understand the molecular factors triggering immune defense against the virus and to develop countermeasures to hinder its spread. Using in silico analyses, we showed that human major histocompatibility complex (MHC) class I cell-surface molecules vary in their capacity for binding different SARS-CoV-2-derived epitopes, i.e., short sequences of 8-11 amino acids, and pinpointed five specific SARS-CoV-2 epitopes that are likely to be presented to cytotoxic T-cells and hence activate immune responses. The identified epitopes, each one of nine amino acids, have high sequence similarity to the equivalent epitopes of SARS-CoV virus, which are known to elicit an effective T cell response in vitro. Moreover, we give a structural explanation for the binding of SARS-CoV-2-epitopes to MHC molecules. Our data can help us to better understand the differences in outcomes of COVID-19 patients and may aid the development of vaccines against SARS-CoV-2 and possible future outbreaks of novel coronaviruses.https://www.mdpi.com/2076-393X/8/3/408SARS-CoV-2COVID-19SARS-CoVin silico analysisMHC class I epitopesHLA
spellingShingle Vipin Ranga
Erik Niemelä
Mahlet Z. Tamirat
John E. Eriksson
Tomi T. Airenne
Mark S. Johnson
Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
Vaccines
SARS-CoV-2
COVID-19
SARS-CoV
in silico analysis
MHC class I epitopes
HLA
title Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
title_full Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
title_fullStr Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
title_full_unstemmed Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
title_short Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better Understanding of COVID-19 Disease—Paving the Way for Vaccine Development
title_sort immunogenic sars cov 2 epitopes in silico study towards better understanding of covid 19 disease paving the way for vaccine development
topic SARS-CoV-2
COVID-19
SARS-CoV
in silico analysis
MHC class I epitopes
HLA
url https://www.mdpi.com/2076-393X/8/3/408
work_keys_str_mv AT vipinranga immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment
AT erikniemela immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment
AT mahletztamirat immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment
AT johneeriksson immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment
AT tomitairenne immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment
AT marksjohnson immunogenicsarscov2epitopesinsilicostudytowardsbetterunderstandingofcovid19diseasepavingthewayforvaccinedevelopment